U.S. markets close in 3 hours 9 minutes
  • S&P 500

    3,774.97
    +96.54 (+2.62%)
     
  • Dow 30

    30,204.27
    +713.38 (+2.42%)
     
  • Nasdaq

    11,130.51
    +315.08 (+2.91%)
     
  • Russell 2000

    1,770.13
    +61.26 (+3.58%)
     
  • Crude Oil

    86.46
    +2.83 (+3.38%)
     
  • Gold

    1,736.80
    +34.80 (+2.04%)
     
  • Silver

    21.26
    +0.68 (+3.28%)
     
  • EUR/USD

    0.9972
    +0.0145 (+1.48%)
     
  • 10-Yr Bond

    3.6110
    -0.0400 (-1.10%)
     
  • GBP/USD

    1.1454
    +0.0135 (+1.19%)
     
  • USD/JPY

    144.1450
    -0.4750 (-0.33%)
     
  • BTC-USD

    20,025.29
    +637.38 (+3.29%)
     
  • CMC Crypto 200

    455.13
    +9.69 (+2.18%)
     
  • FTSE 100

    7,086.46
    +177.70 (+2.57%)
     
  • Nikkei 225

    26,992.21
    +776.42 (+2.96%)
     

Is It Time To Consider Buying Viemed Healthcare, Inc. (TSE:VMD)?

·3 min read

While Viemed Healthcare, Inc. (TSE:VMD) might not be the most widely known stock at the moment, it led the TSX gainers with a relatively large price hike in the past couple of weeks. With many analysts covering the stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. But what if there is still an opportunity to buy? Let’s take a look at Viemed Healthcare’s outlook and value based on the most recent financial data to see if the opportunity still exists.

Check out our latest analysis for Viemed Healthcare

What's The Opportunity In Viemed Healthcare?

Great news for investors – Viemed Healthcare is still trading at a fairly cheap price according to my price multiple model, where I compare the company's price-to-earnings ratio to the industry average. I’ve used the price-to-earnings ratio in this instance because there’s not enough visibility to forecast its cash flows. The stock’s ratio of 29.23x is currently well-below the industry average of 39.26x, meaning that it is trading at a cheaper price relative to its peers. Viemed Healthcare’s share price also seems relatively stable compared to the rest of the market, as indicated by its low beta. If you believe the share price should eventually reach its industry peers, a low beta could suggest it is unlikely to rapidly do so anytime soon, and once it’s there, it may be hard to fall back down into an attractive buying range.

What kind of growth will Viemed Healthcare generate?

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. Though in the case of Viemed Healthcare, it is expected to deliver a relatively unexciting earnings growth of 2.5%, which doesn’t help build up its investment thesis. Growth doesn’t appear to be a main reason for a buy decision for Viemed Healthcare, at least in the near term.

What This Means For You

Are you a shareholder? Even though growth is relatively muted, since VMD is currently trading below the industry PE ratio, it may be a great time to increase your holdings in the stock. However, there are also other factors such as capital structure to consider, which could explain the current price multiple.

Are you a potential investor? If you’ve been keeping an eye on VMD for a while, now might be the time to make a leap. Its future profit outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy VMD. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed assessment.

It can be quite valuable to consider what analysts expect for Viemed Healthcare from their most recent forecasts. So feel free to check out our free graph representing analyst forecasts.

If you are no longer interested in Viemed Healthcare, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here